Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E24.05 EPS (ttm)2.54 Insider Own0.16% Shs Outstand1.65B Perf Week0.11%
Market Cap100.97B Forward P/E18.86 EPS next Y3.24 Insider Trans-0.13% Shs Float1.63B Perf Month-3.94%
Income4.23B PEG2.20 EPS next Q0.67 Inst Own71.30% Short Float0.46% Perf Quarter5.11%
Sales20.57B P/S4.91 EPS this Y184.60% Inst Trans1.22% Short Ratio1.34 Perf Half Y12.41%
Book/sh9.02 P/B6.78 EPS next Y8.21% ROA12.60% Target Price63.10 Perf Year8.12%
Cash/sh4.31 P/C14.18 EPS next 5Y10.95% ROE28.20% 52W Range46.01 - 66.10 Perf YTD4.62%
Dividend1.56 P/FCF61.27 EPS past 5Y4.20% ROI19.80% 52W High-7.50% Beta1.17
Dividend %2.55% Quick Ratio1.50 Sales past 5Y-1.80% Gross Margin72.60% 52W Low32.88% ATR1.09
Employees25000 Current Ratio1.60 Sales Q/Q6.70% Oper. Margin27.30% RSI (14)44.73 Volatility1.47% 1.79%
OptionableYes Debt/Eq0.57 EPS Q/Q-28.20% Profit Margin20.60% Rel Volume0.57 Prev Close61.24
ShortableYes LT Debt/Eq0.47 EarningsOct 26 BMO Payout60.70% Avg Volume5.57M Price61.14
Recom2.50 SMA20-0.71% SMA50-2.83% SMA2006.38% Volume3,192,233 Change-0.16%
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Nov-22-17 10:32AM  Inside Exelixiss Label Expansion Collaborations for Cabozantinib Market Realist
06:59AM  Bristol-Myers Squibb to Take Part in Evercore ISI Biopharma Conference Business Wire
Nov-20-17 08:24AM  Roche Cancer Drug Rises To Challenge Merck, Bristol-Myers Forbes
06:00AM  Merck & Co., Inc. Stocks Decline Is a Reason to Get In Now InvestorPlace
Nov-19-17 11:43AM  3 Biotech Stocks to Be Thankful for This Year Motley Fool
Nov-18-17 10:37AM  10 Frightening Lung-Cancer Statistics and 3 Top Companies Looking to Do Something About It Motley Fool
Nov-17-17 10:30AM  Novartis on the Street: Analysts Recommendations in November Market Realist
10:12AM  Why Its Time to Put Pfizer Inc. Stock on Your Watchlist InvestorPlace
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Nov-16-17 08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:13AM  Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo Zacks
Nov-15-17 08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:36AM  Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate Benzinga
Nov-14-17 02:35PM  Understanding Sanofis Revenues by Segment in 3Q17 Market Realist
Nov-13-17 07:37PM  [$$] Arcus Biosciences Rounds Up $107 Million for Cancer Combination Therapy The Wall Street Journal
03:06PM  Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II Zacks
11:54AM  ETFs with exposure to Bristol-Myers Squibb Co. : November 13, 2017 Capital Cube
10:08AM  Which Will Pfizer Buy? Biogen or Bristol-Myers Squibb Barrons.com
08:28AM  Nektar Therapeutics' stock rockets toward near 17-year high after upbeat trial data MarketWatch
Nov-12-17 11:55PM  First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 PR Newswire
Nov-11-17 05:54PM  First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 PR Newswire
Nov-10-17 04:13PM  BMS-Pfizer Alliance to Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation Business Wire
12:25PM  Are Bristol-Myers Squibb Companys (BMY) Interest Costs Too High? Simply Wall St.
07:00AM  Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003 Business Wire
06:30AM  U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Business Wire
Nov-09-17 11:10AM  Pharma ETFs Down Post Q3 Earnings Zacks
09:01AM  Analysts Recommendations for Celgene in November 2017 Market Realist
08:00AM  Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors Business Wire
Nov-08-17 10:12AM  Infinity (INFI) Q3 Loss Narrower than Expected, View Intact Zacks
06:59AM  Bristol-Myers Squibb to Take Part in Jefferies London Healthcare Conference Business Wire
Nov-07-17 08:35AM  Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
08:00AM  Bristol-Myers Squibb to Highlight Clinical and Translational Research at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting Business Wire
07:50AM  New Research: Key Drivers of Growth for Coty, Bristol-Myers Squibb, Carnival, Agenus, Steel Dynamics, and Impax Labs - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
06:02AM  The Only 3 Big Pharma Companies Growing Market Share Motley Fool
Nov-06-17 09:50AM  Outcome Health losing major advertisers following allegations of misleading clients American City Business Journals
09:00AM  Bristol-Myers Squibbs Valuations after Its 3Q17 Earnings Market Realist
08:30AM  BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax GlobeNewswire
08:09AM  The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical Zacks
07:31AM  Bristol-Myers Squibbs Major Developments in 3Q17 Market Realist
07:00AM  Tax Reform: A Back Door To Killing Health Care, Medicare, And More Forbes
06:59AM  Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC) Business Wire
Nov-05-17 10:00AM  PHOTO ADVISORY: Eric Stonestreet Visits Lung Cancer Alliances Lung Love Walk Houston to Raise Awareness of Cancer Research Business Wire
Nov-03-17 10:31AM  Bristol-Myers Squibbs 3Q17 Earnings: Immunoscience Products Market Realist
09:05AM  Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright Zacks
09:01AM  Eliquis: A Look at BMYs Blockbuster Cardiovascular Drug in 3Q17 Market Realist
07:31AM  Bristol-Myers Squibbs 3Q17 Earnings: Virology Products Market Realist
06:54AM  Zacks.com highlights: Bristol-Myers Squibb, Quintiles IMS Holdings, Intel, CoreSite Realty and Curtiss-Wright Zacks
Nov-02-17 11:55AM  ETFs with exposure to Bristol-Myers Squibb Co. : November 2, 2017 Capital Cube
10:32AM  Bristol-Myers Squibbs 3Q17 Earnings: Opdivo Market Realist
09:03AM  Bristol-Myers Squibbs 3Q17 Earnings: Oncology Portfolio Market Realist
08:54AM  5 Biotech and Pharma Stocks with Key FDA Catalysts this November Zacks
08:27AM  The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate Zacks
07:34AM  Bristol-Myers Squibbs 3Q17 Performance Market Realist
06:59AM  Bristol-Myers Squibb to Showcase Companys Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting Business Wire
Nov-01-17 04:28PM  Top Stock Reports for AbbVie, Union Pacific & Bristol-Myers Zacks
10:31AM  Why Did Merck & Company Fall on October 30? Market Realist
10:18AM  Pfizer Inc. Stock Earnings Were a Snooze But Thats Good InvestorPlace
09:37AM  Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017 Capital Cube
06:59AM  Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship in Support of Promising Biotech Companies in New York Business Wire
Oct-31-17 08:26AM  MSF charity secures generic hepatitis C drugs for $1.40 a day Reuters
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
07:52AM  Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon Benzinga
Oct-30-17 02:49PM  Bristol-Myers Squibb Bulls Take a Short Break TheStreet.com
12:37PM  Bristol-Myers Squibb Co. Value Analysis (NYSE:BMY) : October 30, 2017 Capital Cube
10:59AM  Merck shares dive after multiple firms downgrade on cancer drug withdrawal CNBC
10:44AM  Why What's Bad for Merck Is Good For Bristol-Myers Barrons.com
09:59AM  8 Technical Levels Highlighted On Monday's PreMarket Prep Benzinga
08:30AM  FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax in Patients with Advanced Breast Cancer GlobeNewswire
08:02AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
06:59AM  European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma Business Wire
Oct-27-17 04:06PM  Edited Transcript of BMY earnings conference call or presentation 26-Oct-17 2:30pm GMT Thomson Reuters StreetEvents
11:42AM  Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat Zacks
10:17AM  Company News For Oct 27, 2017 Zacks
08:50AM  Pharma Stock Roundup: Lilly Tops on All Fronts, Mixed Results from Bristol-Myers Zacks
08:30AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : October 27, 2017 Capital Cube
Oct-26-17 07:07PM  These 'safety' stocks become dangerous during expansion CNBC Videos
06:42PM  Cramer: In an economic expansion, these 'safety' stocks b... CNBC Videos
05:58PM  Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin TheStreet.com
04:03PM  Celgene Results Called 'Alarming,' As Alexion, Bristol Mixed Investor's Business Daily
03:43PM  Soaring bond yields could halt the stock market rally Yahoo Finance
02:33PM  Should You Be Worried After Bristol-Myers Squibb's Q3 Results? Motley Fool
02:11PM  EarningsWatch: Celgene tanks and Twitter spikes ahead of Amazon, Alphabet reports MarketWatch
01:48PM  Big movers in the Thursday Blitz CNBC Videos
01:02PM  US STOCKS-Upbeat earnings keep Wall St on firm footing Reuters
12:45PM  M2Gen® Announces Bristol-Myers Squibb's Participation in ORIEN Avatar Research Program PR Newswire
12:41PM  Bristol-Myers Squibb Co (BMY) Stock Falls on Earnings Miss InvestorPlace
11:41AM  Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus Zacks
11:25AM  Bristol-Myers sales in line, but profit margins worsen Reuters
10:30AM  Bristol-Myers: More Bad Medicine for the Market Barrons.com
10:09AM  US STOCKS-Dow advances at open; Celgene holds back S&P, Nasdaq Reuters
09:11AM  What Do Analysts Project for Bristol-Myers Squibb in 3Q17? Market Realist
08:10AM  Bristol-Myers Squibb Company to Host Earnings Call ACCESSWIRE
07:41AM  Bristol-Myers Squibb Could Post Growth in 3Q17 Market Realist
07:23AM  Bristol-Myers Squibb shares decline 2% on Q3 profit miss, revenue beat; updated 2017 consensus MarketWatch
07:23AM  Bristol-Myers misses 3Q profit forecasts Associated Press
07:15AM  Bristol-Myers (BMY) Q3 Earnings Miss Estimates Zacks
07:01AM  Bristol Myers posts in-line sales, but profit margins worsen Reuters
06:59AM  Bristol-Myers Squibb Reports Third Quarter Financial Results Business Wire
Oct-25-17 04:47PM  What Analysts Estimate for Bristol-Myers Squibbs 3Q17 Earnings Market Realist
09:49AM  Drug Stock Q3 Earnings Roster for Oct 26: GILD, BMY & More Zacks
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreements with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; clinical research collaborations with Array BioPharma, Novartis, Clovis Oncology, Inc., and Daiichi Sankyo; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMay 14Option Exercise0.0014,551014,551Jun 08 04:51 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM